Evidence map›Paper›PMID 36212797›Full record

SynthesisKidney cancer (Clifton, Va.)2022

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer.

Ana Filipa Palma Dos Reis, Diana Simão, Thomas Odeny, Chiara Rodrigues, Mário Fontes-Sousa, Ricardo da Luz, Rajasree Pia Chowdry, Sarah J Welsh, Channing Paller, Pedro C Barata

Open access · diamondAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Kidney cancer (Clifton, Va.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Ana Filipa Palma Dos ReisDepartment of Medical Oncology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Diana SimãoDepartment of Medical Oncology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Thomas OdenyNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Chiara RodriguesDepartment of Medical Oncology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Mário Fontes-SousaDepartment of Medical Oncology, CUF TEJO, Lisbon, Portugal.
Ricardo da LuzDepartment of Medical Oncology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
Rajasree Pia ChowdryDepartment of Medicine, Section of Hematology/Oncology, Louisiana State University, New Orleans, LA, USA.
Sarah J WelshDepartment of Medical Oncology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Channing PallerDepartment of Medical Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Pedro C BarataDeming Department of Medicine, Hematology/Oncology Section, Tulane Medical School, New Orleans, LA, USA.
Unidade Local de Saúde de São José · PTCambridge University Hospitals NHS Foundation Trust · GBCUF Porto Hospital · PTJohns Hopkins University · USLouisiana State University · USNational Institutes of Health · USTulane Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses.

objectiveThe objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features.

methodsWe performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords "renal cell cancer" and "immune checkpoint inhibitors" and equivalents were used and all original publications between July 2016 and July 2021 were included.

resultsWe included a total of 14 publications, including two clinical trials and 12 case series. The most frequent histologies were papillary (up to 75-100%), unclassified (up to 34%) and chromophobe (up to 28%). ICI monotherapy showed some activity in both 1st and 2nd line with response rates up to 27%. ICI combination regimens yielded better activity than ICI monotherapy but, overall, a heterogeneous efficacy was noted across histologies. Overall, outcomes of ICIs were superior in tumors with sarcomatoid/rhabdoid features.

conclusionThe observed activity of ICI-based therapies was heterogeneous. Combination regimens, papillary subtype and sarcomatoid/rhabdoid features were associated with higher responses. These findings might help treatment decisions and require further validation.

Indexed as

advancedimmune checkpoint inhibitorimmunotherapyNon clear cell renal cell cancersystematic review

Identifiers

PMID36212797
PMCPMC9490428
OpenAlexW4290081409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.